SHORT-TERM 1,25-DIHYOROXYVITAMIN D3ADMINISTRATION RAISES SERUM OSTEOCALCIN IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS

Abstract

In order to evaluate whether l,25-d1hydroxyvitam1n D₃ [l,25(0H)₂D₃] could increase the serum concentration of osteocalcin¹ (BGP) in patients with post-menopausal osteoporosis, we administered 2 μg⁄d of 1,25(OH)₂D₃ to 14 patients with biopsy proven osteoporosis for two weeks. An additional 13 age and sex-matched patients with osteoporosis received no drug and served as the control. Administration of l,25(0H)₂D₃ significantly Increased the serum concentration of 1,25(OH)₂D from 31±2 SE to 56±5 pg⁄ml (p2D was a significant Increase in BGP from 3.9±0.6 to 6.4±0.9 ng⁄ml (p2D₃ administration is effective 1n raising BGP concentrations in patients with post-menopausal osteoporosis.